小秋
Lv11
40 积分
2024-02-19 加入
-
Atezolizumab and bevacizumab plus transarterial chemoembolization and hepatic arterial infusion chemotherapy for patients with high tumor burden unresectable hepatocellular carcinoma: A multi-center cohort study
1小时前
已完结
-
Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study
9天前
已完结
-
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study
9天前
已完结
-
Antibody–drug conjugates in lung and breast cancer: current evidence and future directions—a position statement from the ETOP IBCSG Partners Foundation
10天前
已完结
-
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
-
Renal Cell Carcinoma
1个月前
已完结
-
Biomarkers for immunotherapy of hepatocellular carcinoma
2个月前
已完结
-
Extracorporeal Membrane Oxygenation Support in Potential Organ Donors for Brain Death Determination
2个月前
已完结
-
Systems toxicology approaches for understanding the joint effects of environmental chemical mixtures
2个月前
已完结
-
Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Phase II Multicenter Study
3个月前
已完结